Abingworth Management Inc

Item 5. Fees and Compensation

    A. Compensation

Abingworth’s compensation is negotiable and varies, but typically Abingworth charges each Advisory
Client an annual management fee. In addition, Abingworth affiliates that serve as general partners of each
of the Bioventures Funds and the CCD Funds (the “General Partners”) receive a percentage of net
profits distributed to the Investors in such Advisory Client as its “carried interest”.

AMI receives a negotiated service fee from ALLP equal to a percentage of the operating expenses incurred
by AMI in the course of performing its duties. The expected operating expenses of AMI are set forth in a
mutually agreed upon budget prior to the beginning of the fiscal year.

Please note that pursuant to Carlyle’s acquisition of Abingworth, Abingworth’s compensation practice is
anticipated to change in the future. Such changes will be reflected in the respective Advisory Client(s)’
offering materials and / or amended brochure(s), as applicable.

Bioventures Funds and CCD Funds’ fees

The General Partners of the Bioventures Funds generally receive a 2% management fee in the form of
“General Partner’s Share” in accordance with the Partnership Agreement. Such management fees are a
percentage of an Advisory Client’s total commitments during such Advisory Client’s investment period
(generally 5 years) and are then reduced over time as set out in the Fund’s Partnership Agreement.

The General Partner of ACCD2 receives management fees during the Advisory Client’s investment period
ranging from 0.75% to 1.50% of total commitments to the Advisory Client, plus 0.5% to 0.75% of
cumulative amounts invested, committed or reserved in connection with specific investments, depending

Abingworth Management Inc.
Form ADV Part 2A

on the category of Investor. After the investment period the Advisory Client’s management fees range
from 1.0% to 1.5% of cumulative amounts invested, committed or reserved in connection with specific
investments, depending on the category of Investor. The General Partner of Abingworth Clinical Co-
Development Fund 2 Co-Investment LP receives a fixed annual management fee.

Such management fees are negotiated with the Investors in each Advisory Client. The Manager’s fees are
funded out of the General Partner’s Share and there are no charges for the Advisory Client in this regard.

    B. Billing

The Bioventures Funds and the CCD Funds’ management fees are payable quarterly in advance from the
commencement date of the Advisory Client.

    C. Other expenses

Each of the Bioventures Funds and the CCD Funds is responsible for and does incur other expenses in
addition to the management fee payable. These expenses typically include establishment costs, legal, tax,
administrators and audit fees, the cost of Investor and advisory committee meetings and third- party costs
arising from transactions whether completed or uncompleted. The expenses are set out in the Partnership
Agreement.

    D. Advancement of Fees

See B. above.

    E. Other Compensation to Supervised Persons from Sales of Securities or Other
       Investment Products

Not applicable.

Item 7. Types of Clients

AMI provides advice and services to the Manager for its use in managing the Advisory Clients. The
Manager’s clients are the Advisory Clients. Investors in the Advisory Clients include sovereign wealth
funds, pension funds, fund of funds, insurance companies, private banks, foundations, endowments, family
offices, high net worth individuals and other institutions. The Advisory Clients qualify for exemption from
the definition of “investment company” under Section 3(c) (1) or Section 3(c) (7) of the 1940 Act.
Investors must meet the requirements for an “accredited investor” under the Securities Act of 1933, as
amended (the “1933 Act”) and a “qualified purchaser” under the 1940 Act.

In general, the minimum investment in the Advisory Clients ranges from $50,000 to $25,000,000 with the
General Partner reserving the right to accept capital commitments of lesser amounts at its discretion.